The new year has come, and Abbott Labs' spinoff of its branded pharmaceuticals division into the new company AbbVie is complete. AbbVie is getting all of the attention from analysts at the moment because of its powerhouse arthritis drug, Humira, which generates the bulk of the revenue for the company -- but what about Abbott Labs? In this video, Motley Fool health care bureau chief Brenton Flynn tells us what he thinks of the trimmer new Abbott sans the branded pharmaceuticals, and why it reminds him a lot of Johnson & Johnson .
The article What Should You Think of the New Abbott Labs? originally appeared on Fool.com.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.